Apjohn ventures
VC Fund
Kalamazoo, United States
Apjohn ventures is a VC fund in Kalamazoo focused on Health Care and Biotechnology. Apjohn Ventures Fund is a new venture capital firm based in Kalamazoo, Michigan established to invest primarily in early stage life sciences companies across the Midwest. The goal of the Fund is to provide investors with superior financial returns by making equity investments in innovative life sciences companies with sustainable and outstandinggrowth potential.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 13%
Last updated:
For AI agents: llms.txt
Industries Apjohn ventures invests in
Stages Apjohn ventures invests in
Countries Apjohn ventures invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.5M–$39M
- Series C
- $3M–$34M
Investment Focus
Industry
- Health Care 7 (47%)
- Biotechnology 7 (47%)
- Life Science 4 (27%)
- Therapeutics 4 (27%)
- Medical 3 (20%)
Stage
- Series A 5 (33%)
- Series C 2 (13%)
- Funding Round 2 (13%)
- Series B 1 (7%)
- Series D 1 (7%)
Country
- United States 8 (53%)
- Canada 1 (7%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Donald Parfet
Founder and General Partner
|
Founder and General Partner | Total investments: 7 | Find email | |
Deb Cronkite
Controller
|
Controller | Total investments: 0 | Find email | |
Mina Patel Sooch
Founder and General Partner
|
Founder and General Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tetra Therapeutics is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Fragile X syndrome, Alzheimer's disease, traumatic brain injury, and other brain disorders. | $5M / Series A / Nov 29, 2016 | ||
| Tetra Discovery Partners provides consulting services in drug discovery and development. They partner with Universities to commercialize intellectual property and conduct proprietary research on diseases affecting the central nervous system.Their research focuses on developing new treatments for depression and schizophrenia. Severe forms ofdepression affect 2–5% of the US population, while mood disorders impact 7% of the world’s population and rank among the top ten causes of disability. | $5M / Series A / Nov 29, 2016 | ||
| Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of currenttreatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact. | $59.5M / Series D / Apr 21, 2014 | ||
| CytoPherx (formerly Nephrion) clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system. | $34M / Series C / Jan 04, 2012 | ||
| Svelte Medical Systems (Svelte) is a privately held company focused on delivering novel products in the $5 billion coronary stent market. Its mission is to address key clinical issues in the stent market by improving stent deliverability, reducing cost, and dramatically improving the safety of the device compared to current market products.Sveltehas developed the lowest profile and most deliverable balloon-expandable stent in the market, along with technology to create a non-thrombogenic, non-inflammatory Drug-Eluting Stent (DES). Svelte was started by Robert Fischell, David Fischell, and Tim Fischell in 2007. | Debt Financing / Nov 07, 2009 | ||
| Ikano Therapeutics Inc., a specialty pharmaceutical company, focuses on developing nasal spray drug products. | $18M / Series B / Mar 30, 2009 | ||
| Sierra Oncology is a late-stage biopharmaceutical company on a mission to deliver targeted therapies that treat rare forms of cancer. The company harnesses its deep scientific expertise to identify compounds that target the root cause of disease. Sierra Oncology's team takes an evidence-based approach to understand the limitations of currenttreatments and explore new ways to change the cancer treatment paradigm. Sierra Oncology is transforming promise into patient impact. | $12.5M / May 30, 2008 | ||
| CytoPherx (formerly Nephrion) clinical stage medical device company addressing inflammation-based diseases and conditions. The company’s products are custom configurations of a proprietary selective cytopheresis-based inflammation modulating system. | $2.5M / Series A / Oct 22, 2007 | ||
RenaMed Biologics
|
RenaMed Biologics a biotechnology company, engages in the development and commercialization of therapies for the treatment of diseases associated with compromised kidney function. The company focuses on patients suffering from acute renal failure and additional indications where kidney function is compromised. It develops RBI-01, which utilizesphysiologically active human renal epithelial cells and administered ex vivo, to replace and maintain severely compromised, or lost kidney functions due to illness, or trauma. The company was founded in 1995 as Nephros Therapeutics, Inc. and changed its name to RenaMed Biologics, Inc. in 2005. RenaMed Biologics, Inc. is based in Lincoln, Rhode Island. | $40M / Sep 07, 2006 | |
| Ikano Therapeutics Inc., a specialty pharmaceutical company, focuses on developing nasal spray drug products. | $39.1M / Series A / Aug 15, 2006 | ||
| See all 15 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Apjohn ventures invest in?
Apjohn ventures invests primarily in Health Care, Biotechnology and Life Science startups, most often at Series A and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Apjohn ventures's check size?
Apjohn ventures typically joins rounds of $2.5M–$39M at Series A and $3M–$34M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Apjohn ventures participates in.
How do I contact Apjohn ventures?
Public channels for Apjohn ventures include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Apjohn ventures?
The team at Apjohn ventures includes Donald Parfet (Founder and General Partner), Deb Cronkite (Controller) and Mina Patel Sooch (Founder and General Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
